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APPENDIX I - EXCERPTS FROM THE SETTLEMENT
Appendix I contains excerpts from the June 20, 1997 tobacco settle-
ment cited by the authors of the articles. The full document is
available at <http://www.stic.neu.edu/settlement/6-20-settle.htm>.
Portions of the settlement contained in Appendix I are indicated in
the Table of Contents in bold typeface. Omitted text is indicated by
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TITLE I: Reformation Of The Tobacco Industry
Title I of the legislation would incorporate and expand upon FDA's
recent regulation of nicotine-containing tobacco products.
The following rules would apply to all tobacco products sold in the
U.S. (including all its territories and possessions, as well as duty-free
shops within U.S. borders). The new regime would be allowed to op-
erate as described below for five years. FDA would have authority to
make revisions even within this period under extraordinary circum-
stances. Thereafter, the FDA would be authorized to review and revise
the rules under applicable Agency procedures.
A. Restrictions on Marketing and Advertising
The advertising and marketing of tobacco products would be drasti-
cally curtailed, including in ways that exceed the FDA rule as origi-
nally promulgated and in ways that have previously been challenged
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on First Amendment grounds. As in the FDA rule the new regime
would:
- Prohibit the use of non-tobacco brand names as brand names of
tobacco products except for tobacco products in existence as of Janu-
ary 1,1995 (897.16(a)) (The citations in this and in the next section
are to Part 897 of the FDA's tobacco regulations, 61 Fed. Reg. 44396
(August 28, 1996)
- Restrict tobacco product advertising to FDA specified media
(897.30(a) (1 )-(2))
- Restrict permissible tobacco product advertising to black text on a
white background except for advertising in adult-only facilities and in
adult publications (897.32(a)-(b))
- Require cigarette and smokeless tobacco product advertisements
to carry the FDA-mandated statement of intended use ("Nicotine De-
livery Device") (897.32(c))
- Ban all non-tobacco merchandise, including caps, jackets or bags
bearing the name, logo or selling message of a tobacco brand
(897.34(a))
- Ban offers of non-tobacco items or gifts based on proof of
purchase of tobacco products (897.34(b))
- Ban sponsorships, including concerts and sporting events, in the
name, logo or selling message of a tobacco brand (897.34(c))
Further, building on and going beyond the FDA rule, the new regime
would:
- Ban the use of human images and cartoon characters - thereby
eliminating Joe Camel and the Marlboro Man - in all tobacco advertis-
ing and on tobacco product packages
- Ban all outdoor tobacco product advertising, including in en-
closed stadia as well as brand advertising directed outside from a retail
establishment (modifies 897.30(a)(1) and extends 897.30(b))
- Prohibit tobacco product advertising on the Internet unless
designed to be inaccessible in or from the United States
- Establish nationwide restrictions in non adult-only facilities on
point of sale advertising with a view toward minimizing the impact of
such advertising on minors. These provisions, which are detailed in
Appendix VII, restrict point of sale advertising that was otherwise per-
mitted in retail establishments by the FDA rule
- Ban direct and indirect payments for tobacco product placement
in movies, television programs and video games
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- Prohibit direct and indirect payments to "glamorize" tobacco use
in media appealing to minors, including recorded and live perform-
ances of music - Without limiting the FDA's normal rulemaking au-
thority in this area, require that the use, in both existing and future
brand styles, of words currently employed as product descriptors (e.g.,
"light" or "low tar") be accompanied by a mandatory disclaimer in
advertisements (e.g., "Brand X not shown to be less hazardous than
other cigarettes"); exemplars of all new advertising and tobacco prod-
ucts labeling shall be submitted to FDA concurrently with their intro-
duction into the marketplace for FDA's ongoing review.
[Source/precedent: FDA Rule; 21 C.F.R. 101.70]
B. Warnings, Labeling and Packaging
The federally-mandated warning labels on cigarettes were last
changed in 1984. Since then a number of countries, including Canada
and members of the European Union, have imposed new warning la-
bels. Further, the Federal Trade Commission's methodology to mea-
sure the "tar" and nicotine yields of cigarettes has been criticized as
producing misleading information.
1. The legislation, through amendments to the Federal Cigarette La-
beling and Advertising Act and the Comprehensive Smokeless To-
bacco Health Education Act, would mandate new rotating warnings,
to be introduced concurrently into the distribution chain on all to-
bacco product packages and cartons, and to be rotated quarterly in all
advertisements. For cigarettes, the warnings would be:
- "WARNING: Cigarettes are addictive"
- "WARNING: Tobacco smoke can harm your children" - "WARN-
ING: Cigarettes cause fatal lung disease"
- "WARNING: Cigarettes cause cancer"
- "WARNING: Cigarettes cause strokes and heart disease"
- "WARNING: Smoking during pregnancy can harm your baby"
- "WARNING: Smoking can kill you"
- "WARNING: Tobacco smoke causes fatal lung disease in non-
smokers"
- "WARNING: Quitting smoking now greatly reduces serious risks to
your health"
For smokeless tobacco products, the warnings would be:
- "WARNING: This product can cause mouth cancer"
- "WARNING: This product can cause gum disease and tooth loss"
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- "WARNING: This product is not a safe alternative to cigarettes"
-"WARNING: Smokeless tobacco is addictive"
For cigarettes, the warnings would occupy 25% of the front panel of
the package (including packs and cartons) and would appear on the
upper portion thereof. The legislation would contain a grandfather
provision for existing brands with flip-top boxes comprising less than
25% of the front panel. For smokeless tobacco products, the warnings
would appear on the principal display panel (e.g., a band around the
can for moist smokeless tobacco products) and would occupy 25% of
the display panel. The warnings would be printed in line with current
Canadian standards (e.g., 17 point type with appropriate adjustments
depending on length of required text) and in an alternating black on
white and white on black format. The size and placement of warnings
in advertisements would follow the requirements set forth in the ex-
isting United Kingdom standards. As described in Appendix I, the
warning text and, where relevant, "tar" and nicotine (or other constit-
uent) yield information would occupy 20% of press advertisements.
Cigarette and smokeless tobacco product packages would also carry
the FDA mandated statement of intended use ("Nicotine Delivery De-
vice") on the side of pack.
2. The FDA would be required to promulgate a rule governing the
testing, reporting and disclosure of tobacco smoke constituents that
the Agency determines the public should be informed of to protect
public health, including, but not limited to "tar," nicotine and carbon
monoxide. This authority would be transferred from the FTC and
would include the authority to require label and advertising disclo-
sures relating to "tar" and nicotine, as well as disclosures by other
means relating to other constituents.
[Source/precedent: Canadian warning regulations; FDA Rule; FDCA,
21 U.S.C. Sec. 360h, with conforming amendment in light of FCLAA]
C. Restrictions on Access to Tobacco Products
Preventing youth access to tobacco products is a major objective of
this legislation and the FDA Rule. Without preventing state and local
governments from imposing stricter measures, the legislation would
incorporate every access restriction of the FDA Rule, and more. As in
the FDA Rule, the legislation would:
- Set a minimum age of 18 to purchase tobacco products
(897.14(a))
- Require retailers to check photo identification of anyone under 27
(897.1 4(b)( 1 )-(2))
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- Establish the basic requirement of face-to-face transactions for all
sales of tobacco products (897.14(c))
- Ban the sale of tobacco products from opened packages
(897.14(d))
- Establish a minimum package size of 20 cigarettes (897.16(b))
- Impose retailer compliance obligations to ensure that all self-ser-
vice displays, advertising, labeling and other items conform with all
applicable requirements (897.14(e))
- Ban the sampling of tobacco products (897.16(d))
- Ban the distribution of tobacco products through the mail, includ-
ing redemption of coupons, except for sales subject to proof of age,
with a review after 2 years by FDA to determine if minors are ob-
taining tobacco products through the mail (goes beyond
897.16 (c) (2) (i))
Building on and going beyond the FDA Rule, the legislation would:
- Ban all sales of tobacco products through vending machines (goes
beyond 897.16(c) (2) (ii))
- Ban self-service displays of tobacco products except in adult-only
facilities. In all other retail outlets, tobacco products must be placed
out of reach of consumers (i.e., behind the counter or under lock-
and-key) or, if on the counter, not visible or accessible to consumers
(goes beyond (897.1 6(c) (2) (ii))
[Source/precedent: FDA Rule]
TITLE H: "Look Back" Provisions/State Enforcement incentives
A central aim of this legislation is to achieve dramatic and immediate
reductions in the number of underage consumers of tobacco prod-
ucts. The legislation accordingly contains a "look-back" provision giv-
ing tobacco product manufacturers significant economic incentives to
take every possible step to ensure that the advertising, marketing and
distribution requirements of this Act are met, and imposing substan-
tial surcharges on the manufacturers in the event that underage to-
bacco-use reduction targets are not achieved.
The "look-back" provision sets targets for the dramatic reduction of
current levels of underage tobacco use (as measured by the University
of Michigan's National High School Drug Use Survey "Monitoring the
Future"). Underage use of cigarette products must decline by at least
30% from estimated levels over the last decade by the fifth year after
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the legislation takes effect, by at least 50% from estimated levels over
the last decade by the seventh year after the legislation takes effect, by
at least 60% from estimated levels over the last decade by the tenth
year after the legislation takes effect, and remain at such reduced
levels or below thereafter. (These required reductions amount to even
steeper declines from current levels of underage smoking.) Underage
use of smokeless tobacco products must decline by at least 25% from
current levels by the fifth year after the legislation takes effect, by at
least 35% from current levels by the seventh year after the legislation
takes effect, by at least 45% from current levels by the tenth year after
the legislation takes effect, and remain at such reduced levels or below
thereafter. FDA will annually assess the prevalence of underage to-
bacco use (based on the methodology employed by the University of
Michigan survey) to determine whether these targets have been met.
If a target has not been met, FDA will impose a mandatory surcharge
on the relevant industry (cigarette or smokeless tobacco) based upon
an approximation of the present value of the profit the industry would
earn over the lives of all underage users in excess of the target (sub-
ject to an annual cap of $2 billion for the cigarette industry (adjusted
each year for inflation) and a comparably derived cap for the smoke-
less tobacco industry). Tobacco product manufacturers could receive
a partial abatement of this surcharge (up to 75%) only if they could
thereafter prove to FDA that they had fully complied with the Act, had
taken all reasonably available measures to reduce youth tobacco use
and had not taken any action to undermine the achievement of the
required reductions.
A fuller description is provided in Appendix V.
In addition, the proposed Act goes well beyond the provisions of the
Synar Amendment's "no tobacco sales to minors" law and related reg-
ulations, 42 U.S.C. § 300X-26, and the Final Rule promulgated there-
under, which became effective February 20,1996 (61 Fed. Reg., June
19,1996). The proposed Act requires the several States to undertake
significant enforcement steps designed to dramatically reduce the in-
cidence of youth smoking, and youth access to tobacco products.
These enforcement obligations are funded by Industry Payments.
Each state must maintain specific levels of enforcement effort, or the
state risks the loss of a significant portion of the health care program
funds otherwise payable to the state under the Act. Amounts withheld
from states not doing an adequate enforcementjob will be reallocated
to states with a superior "no sales to minors" enforcement record. No
state will be held responsible for sales to underage consumers outside
that state's jurisdiction.
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The details of these state enforcement incentives are set forth in Ap-
pendix VI.
TITLE VI: Programs/Funding
TOTAL 25 YEAR PACKAGE FACE VALUE - $368.5 Billion
A. Up Front Commitment - Lump Sum Cash Payment - $10 Billion
1. Payable on Statute Signing Date.
B. Base Annual Payments - 25 Year Total Face Value is $358.5 Billion
(Figures Subject to Inflation Protection and Volume Adjustments)
1. Duration - annual payments in perpetuity
2. Commencement - 12/31 of first full year after statute signing
3. Face Amounts (includes payments from all industry sources): Year
1 2 3 4 5 6-8 9 after
Total Payments $8.5B $9.5B $11.5B $14B $15B $15B $15B $15B
Base Amount: $6B $7B $8B $10B $10B $12.5B $15B $15B
Public Health Trust $2.5B $2.5B $3.5B $4B $5B $2.5B
4. Inflation Protection for Annual Payments
- Greater of 3% or CPI applied each year on previous year, begin-
ning with first annual payment.
5. Adjustment for Volume Decrease (Adult Volume Only) or Total
Volume Increase
- Beginning in year 1; payment made equal to scheduled annual
payment times the ratio of actual relevant domestic tobacco product
unit sales volume to relevant base volume. In the event of a decline in
volume, relevant actual volume and relevant base volume are adult
volume figures; in the event of an increase in volume, relevant actual
volume and relevant base volume are total volume figures. Base vol-
ume is 1996 volume.
- Any reduction in an annual payment will be reduced by 25% of
any increase above the industry's base year net operating profits (after
application of inflator discussed above) from domestic sales of to-
bacco products.
6. Payment Protection
- Provide for payment priority/continuation during bankruptcy/ re-
organization proceedings.
Protocol cannot be rejected in bankruptcy. Obligation for annual pay-
ments responsibility only of entities selling into domestic market
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7. Pass-Through
- In order to promote maximum reduction in youth smoking, the
statute would provide for the Annual Payments to be reflected in the
prices manufacturers charge for tobacco products.
C. Applicability
1. Applicable to All Sellers of Tobacco Products
- Through protocol and statute to protocol signatories.
- Through alternative statutory provisions to non-signatories.
D. Tax Treatment
All payments pursuant to this Agreement (including those pursuant to
Title II) shall be deemed ordinary and necessary business expenses for
the year of payment, and no part thereof is either in settlement of an
actual or potential liability for a fine or penalty (civil or criminal) or
the cost of a tangible or intangible asset.
TITLE VII: Public Health Funds From Tobacco Settlement As Recom-
mended By The Attorneys General For Consideration By The Presi-
dent And The Congress
BASED ON THE PREMISE OF $1 BILLION FOR THE FIRST YEAR
AND GRADUALLY INCREASING TO $1.5 BILLION THEREAFTER,
ADJUSTED FOR INFLATION AFTER THE FIRST YEAR.
BASED ON THE PREMISE OF $1 BILLION FOR SMOKING CESSA-
TION FOR THE FIRST 4 YEARS AND $1.5 BILLION THEREAFTER,
ADJUSTED FOR INFLATION.
(A) ALLOCATION OF GRANT MONIES AMONG PROGRAMS - The
use of moneys under this Section shall be limited to programs estab-
lished under this Section, shall be adjusted for inflation annually from
the effective date, and shall be allocated among such programs as
follows:
(1) $125,000,000 for the first three years and $225,000,000 annually
thereafter to the Secretary of HHS to accomplish the purposes de-
scribed in Paragraph (B) of this Section (Reduction in Tobacco
Usage);
(2) $300,000,000 annually for the FDA to carry out its obligations
under and to enforce the terms of this Act, including for grants to the
states to assist in the enforcement of the provisions of the Act;
(3) $75,000,000 for the first two years, $100,000,000 in the third year,
and $125,000,000 annually thereafter to fund state and local tobacco
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control community based efforts modeled on the ASSIST program,
designed to encourage community involvement in reducing tobacco
use and the enactment and implementation of policies designed to
reduce the use of tobacco products;
(4) $100,000,000 annually to fund research and the development of
methods for how to discourage individuals from starting to use to-
bacco and how to help individuals to quit using tobacco;
(5) Beginning in the second year, $75,000,000 annually for a period
of ten (10) years to compensate events, teams or entries in such
events, who lose sponsorship by the tobacco industry as a result of this
Act, or who currently receive tobacco industry funding to sponsor
events and elect to replace that funding, provided that the event,
team, or entry is otherwise unable to replace its tobacco industry spon-
sorship during those given years. Funds used for this purpose shall
promote a Quit Tobacco Use theme. After a ten year period, no addi-
tional funds shall be used for this purpose and the funds previously
allocated to this purpose shall be used as follows: 50% to supplement
funding of the multimedia campaigns in paragraph (1) of this subsec-
tion; 25% to supplement the funding of the enforcement provisions
of paragraph (2) of this subsection; and 25% to supplement the fund-
ing of community action programs in paragraph (3) of this
subsection.
(B) ESTABLISHMENT OF PROGRAMS BY THE SECRETARY - The
Secretary shall establish programs to accomplish the following
purposes-
(1) the reduction of tobacco product usage, both by seeking to dis-
courage the initiation of tobacco use by persons under the age of 18
and by encouraging current tobacco users to quit through media-
based and non-media based education, prevention and cessation cam-
paigns. The Secretary may make grants to state health departments to
assist in carrying out the purposes of this provision.
(2) the research into and development and public dissemination of
technologies and methods to reduce the risk of dependence and in-
jury from tobacco product usage and exposure;
(3) the identification, testing and evaluation of the health effects of
both tobacco and non-tobacco constituents of tobacco products;
(4) the promulgation of such other rules and regulations as are neces-
sary and proper to carry out the provisions of this Act, as well as the
development of such other programs as the Secretary determines are
consistent with the goals of the Act.
(C) Public Education Campaign - $500,000,000 shall be spent annu-
ally in such multi-media campaigns designed to discourage and de-
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glamorize the use to tobacco products. To carry out such efforts, an
independent non-profit organization with a Board made up of prestig-
ious individuals and the leaders of the major public health organiza-
tions shall be created which shall contract or make grants to non-
profit private entities who are unaffiliated with tobacco manufacturers
or tobacco importers, who have a demonstrated record of working
effectively to reduce tobacco product use and expertise in multi-media
communications campaigns. The independent body shall be author-
ized to contract with state health departments, where appropriate, to
run campaigns for their states and communities. In creating the pro-
gram the Secretary or independent body shall also take into account
the needs of particular populations. The goal shall be the reduction of
tobacco product usage, both by seeking to discourage the initiation of
tobacco use by persons under the age of 18 and by encouraging cur-
rent tobacco users to quit.
(D) Tobacco Use Cessation - For the first 4 years, $1 billion, and there-
after, $1.5 billion of the total amount paid by the tobacco industry
shall be paid into a Trust Fund to be used to assist individuals who
want to quit using tobacco to do so.
Within 12 months the Secretary shall promulgate regulations to gov-
ern (1) the establishment of criteria for and a procedure for the ap-
proval of cessation programs and devices for which payment may be
made under the program, (2) the eligibility requirements for individ-
uals seeking to use moneys from the trust to fund the tobacco cessa-
tion efforts, and (3) the procedures to govern the tobacco cessation
program.
The goal of the tobacco cessation program shall to enable the most
tobacco users possible to receive assistance in their effort to quit using
tobacco by providing financial assistance and identifying the pro-
grams, techniques, and devices that have been shown to be safe and
effective. Benefits to individuals should not be limited to a single ef-
fort, but should be tailored to the needs of individual smokers accord-
ing to standards established by the Secretary using the best available
scientific guidelines.
(E) Public Health Trust Fund Presidential Commission - A Presiden-
tial commission will be appointed to include representatives of the
public health community, Attorneys General, Castano attorneys and
others to determine the specific tobacco-related medical research for
which the $25 Billion Public Health Trust Fund will be used.
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TITLE VIII: Civil Liability
The following provisions would govern actions for civil liability related
to tobacco and health.
A. General
1. Present Attorney General actions (or similar actions brought by or
on behalf of any governmental entity), parens patriae and class ac-
tions are legislatively settled. No future prosecution of such actions.
All "addiction"/dependence claims are settled and all other personal
injury claims are reserved. As to signatory States, pending Congres-
sional enactment, no stay applications will be made in pending ac-
tions, based upon the fact of this resolution, without mutual consent
of the parties.
2. Third-party payor (and similar) actions pending as of 6/9/97 are
not settled, but governed by provisions regarding past conduct set
forth in Section B below.
B. Provisions as to Civil Liability for Past Conduct
The following provisions apply to suits for relief arising from past con-
duct - i.e., suits by persons claiming injury or damage caused by con-
duct taking place prior to the effective date of the Act.
1. All punitive damages claims resolved as part of overall settlement.
No punitive damages in individual tort actions.
2. Individual trials only: i.e., no class actions, joinder, aggregations,
consolidations, extrapolations or other devices to resolve cases other
than on the basis of individual trials, without defendant's consent. Ac-
tion removable by defendant to federal court upon receipt of applica-
tion to, or order of, state court providing for trial or other procedure
in violation of this provision.
3. Except as expressly provided in the Act, FCLAA and applicable case
law unchanged by the Act.
4. Provided that the five negotiating companies enter into the Proto-
col: Protocol manufacturers to enter into joint sharing agreement for
civil liability. Protocol manufacturers not jointly and severally liable
for liability of non-Protocol manufacturers. Trials involving both pro-
tocol and non-Protocol manufacturers to be severed.
5. Permissible parties:
Plaintiffs -
a. Claims of individuals, or claims derivative of such claims, must be
brought either by person claiming injury or heirs.
b. Third-party payor (and similar) claims not based on subrogation
that were pending as of 6/9/97.
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c. Third-party payor (and similar) claims based on subrogation of indi-
vidual claims; no extrapolations, etc.
Defendants
a. maintained only against companies, their assigns, any future fraudu-
lent transferee, and/or entity for suit designated to survive defunct
manufacturer. Actions may be manufacturing successors and
b. Manufacturers of agents agencies and liable vicariously for acts (in-
cluding advertising attorneys).
6. No removal except under paragraph 2 above.
7. The development of "reduced risk" tobacco products after the ef-
fective date of the Act is neither admissible nor discoverable.
8. Statute of limitations: for all actions, individual state laws governing
time periods from injury, discovery, notice or contamination/
violation.
9. Annual aggregate cap for judgments/settlements: 33% of annual
industry base payment (including any reductions for volume decline).
If aggregate judgments/settlements for a year exceed annual aggre-
gate cap, excess does not have to be paid" that year and rolls over.
Any judgments/settlements run against defendant? but give rise to 80-
cent-on-the-dollar credit against annual payment in year paid. Suitable
provision for settlement consultation and permission. Manufacturers
control insurance claims, and any insurance recovery obtained by
manufacturers (net of cost) on account of judgment and/or settle-
ment covered by above sharing arrangement allocated 80% to annual
payments. Manufacturers retain any insurance proceeds on account of
defense costs.
Provision with respect to individual judgments above $1 million:
amount in excess of $1 million not paid that year unless every other
judgment/settlement can be satisfied within the annual aggregate
cap. Excess rolls forward without interest and is paid at the rate of $1
million per year, until the first year that the annual aggregate cap is
not exceeded (at which time the remainder is paid in full). For pur-
poses of this provision, a third-party payor (or similar) action not
based on subrogation is treated as having been brought by a single
plaintiff and is subject to the $1 million rollover on that basis.
10. In the event that the annual aggregate cap is not reached in any
year, a Commission appointed by the President will determine the ap-
propriate allocation of the amount representing the unused amount
of the credit. The Commission will be entitled to consider, among
public health, governmental entities, and other uses of the funds, ap-
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plications for compensation from persons, including nonsubrogation
claims of third party payors, not otherwise entitled to compensation
under the Act.
11. Defense costs paid by manufacturers.
C. Provisions as to Civil Liability for Future Conduct
The following provisions apply to suits for relief arising from future
conduct - i.e., suits claiming injury or damage caused by conduct tak-
ing place after the effective date of the Act.
1. Paragraphs 2, 3, 5, 6, 7, 8, 9, 10 and 11 in Section B apply.
2. No third-party payor (or similar) claims not based on subrogation.
Appendix II - Retail Tobacco Product Seller Penalties
1. The sale of tobacco products to consumers by an unlicensed seller
shall be a criminal violation, and be subject to minimum penalty of
$1,000, or imprisonment, for 6 months, or both, if an individual, or in
the case of a corporation, by a maximum penalty of $50,000. Any State
or local jurisdiction may provide by statute or code more severe
penalties.
2. In addition to any criminal penalties which may be imposed under
any applicable state or local law, a tobacco product licensee may be
subjected to civil sanctions, including penalties, or license suspension
or revocation (on a site-by-site basis), or a combination thereof, for
any violation of the provisions of the State licensing laws regarding
sales to minors. Such sanction shall not exceed the following:
(a) For the first offense within any two year period, $500 or a 3 day
license suspension or both.
(b) For the second offense within any two year period, $1,000 or a 7
day license suspension or both.
(c) For the third offense within any two year period, $2,000 or a 30
day license suspension or both.
(d) For the fourth offense within any two year period, $5,000 or a 6
month license suspension or both.
(e) For the fifth offense within any two year period, $10,000 or 1 year
license suspension or both.
(f) For the sixth and any subsequent offenses within any two year pe-
riod, $25,000 or a revocation of license with no possibility of reinstate-
ment for a period of three years.
(g) Permanent license revocation is mandatory for the tenth offense
within any two year period.
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Each state must enact a statutory or regulatory enforcement scheme
that provides substantially similar penalties to the minimum federal
standards for a retail licensing program.
[Source/Precedent: Washington State Alcohol Licensing Act]
Appendix VI: State Enforcement Incentives
The details of the state enforcement incentives are as follows:
In addition to FDA and other federal agency, state attorney general
and other existing state and local law enforcement authority under
current law, the proposed Act requires the following:
A. States must have in effect a "no sales to minors" law providing that
it is unlawful for any manufacturer, retailer or distributor of tobacco
products to sell or distribute any such products to any persons under
the age of 18. (42 U.S.C. §300X-26(a) (1); 45 C.F.R. §96.130(b)). This
state statutory requirement remains in addition to the federal regula-
tory prohibitions on retail sales of tobacco products to children and
adolescents (also defined as persons under the age of 18) adopted by
the FDA in its August 28, 1996 Final Rule (to be codified at 21 C.F.R.
§897.14 et seq.);
B. States must conduct random, unannounced inspections at least
monthly, and in communities geographically and statistically repre-
sentative of the entire state and its youth population to ensure compli-
ance with the "no sales to minors" law, and implement "any other
action which the state believes are necessary to enforce the law." (goes
further than 45 C.F.R. §96.130(c), 96.1 30(d)(1 ),(d)(2);
C. States must conduct at least 250 random, unannounced inspections
of retailer compliance with the "no sales to minors" law per year for
each 1 million of resident population, as determined by the most re-
cent decennial census. In the case of tribes, tribes must conduct no
fewer than 25 such inspections per location of point of sale to con-
sumers per year, conducted throughout the year.
Annual State Reporting Requirements
As a condition to receiving any moneys due and payable pursuant to
the Act, States must annually submit a report to the FDA and the
States must make their reports public (except as provided in (C) be-
low) within the state. Such state reports must include at least the
following:
[VOL. 2:122
APPENDIX I - EXCERPTS FROM THE SETTLEMENT
A. A detailed description of enforcement activities undertaken by the
state and its political subdivisions during the preceding federal fiscal
year;
B. A detailed description of the state's progress in reducing the availa-
bility of tobacco products to individuals under the age of 18, includ-
ing the detailed statistical results of the mandated compliance checks;
C. A detailed description of the methods used in the compliance
checks, and in identifying outlets which were tested, with the FDA pro-
viding the state appropriate confidentiality safeguards for information
provided to the agency regarding the timing and investigative tech-
niques of state compliance checks that depend for their continued
efficacy upon such confidentiality;
D. A detailed description of strategies the state intends to utilize in the
current and succeeding years to make further progress on reducing
the availability of tobacco products to children and adolescents; and
E. The identity of the "single state agency" responsible for fulfilling
the Synar Amendment and the Act's requirements, including the co-
ordination and report of state efforts to reduce youth access to to-
bacco products sold or offered for sale in the state. (strengthens and
extends beyond 45 C.F.R. §96.130(e) by adding greater detail to the
requirements and transferring reporting obligation of states to FDA
from HHS)
Required Attainment Goals for State Enforcement
The FDA is required to make an annual determination, prior to allo-
cating any moneys allocated to the states under the proposed Act for
the purposes of defraying public health care program expenditures
(but not including or conditioning moneys made available under the
Act for the payment of private claims), as to whether each state has
"pursued all reasonably available measures to enforce" the prohibition
on sales of tobacco products to children and adolescents.
In addition to the criteria set forth in 45 C.F.R. §96.130, the proposed
Act will require the FDA to find presumptively that the state has not
"pursued all reasonably available measures to enforce" the "no sales to
minors law" unless the state has achieved, in the following years, the
following compliance rate results for the retail compliance checks re-
quired by the Act:
Federal Fiscal Year Retail Compliance Check
Under Review Performance Target
5th Year after year of 75%
enactment of Act
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7th Year after year of 85%
enactment of Act
10th Year after year of 90%
enactment of Act and annually thereafter
These compliance percentages are expressed as the percentage of the
random, unannounced compliance checks conducted pursuant to the
Act for which the retailer refused sale of tobacco products to the po-
tential underage purchaser. (note: these performance targets are far
more stringent on the states than those in the Synar Amendment,
which sets as a "final goal" a target of no less than 80% (i.e., an inspec-
tion failure rate of no more than 20%) within "several years." See 45
C.F.R. §96.130. In addition, the proposed Act's targets are mandatory,
uniform national minimum performance requirements, while the
Synar Amendment calls for HHS simply to "negotiate" an "interim
performance target" beginning in 1998).
Reduction of Money Allocated to State Not Meeting Performance
Targets
If a state does not meet the Act's "no sales to minors" performance
targets for retail compliance checks, then the FDA may refuse to pay
to that noncomplying state certain moneys otherwise payable to that
state under the proposed Act. No state shall be held responsible for
sales to underage consumers outside that state's jurisdiction. Specifi-
cally, the FDA may withhold from such state an amount equal to 1%
of moneys otherwise payable to that state under the Act to defray
health care expenditures of public programs of medical assistance for
each percentage point by which the state's performance on its
mandatory compliance checks fails to meet the required performance
targets for that year. In no event may the FDA withhold more than
20% of the money otherwise allocable to such state under the Act for
such purposes.
The FDA shall reallot any Withhold Amounts, once final, to states that
exceed the Act's Performance Targets, in amounts and by an alloca-
tion formula determined by the agency to reward those states with the
best record of reducing youth access to tobacco products.
Appeal Following Withhold
Upon notice from the FDA of a withhold of moneys (the "Withhold
Amount") allocable to the state under the Act, a state subject to such
notice of withhold may petition the agency for a release and disburse-
ment of the Withhold Amount, and shall give timely written notice of
such petition to the attorney general for that state and to all tobacco
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product manufacturers. The agency shall hold, and invest in interest
bearing securities of the United States government or its agencies, any
Withhold Amounts subject to a pending petition for release and dis-
bursement or related appeal until final disposition of such petition
and appeal.
In the case of petition by a state for a release and disbursement of a
Withhold Amount, the agency's decision on whether to grant such a
petition, and the amount thereby released and disbursed, if any, shall
be based on whether:
(1) the state has acted in good faith and in full compliance with the
Act, and any agency rules or regulations promulgated thereunder;
(2) the state has pursued all reasonably available measures to attain
the Retail Compliance Check Performance Targets and Youth Smok-
ing Reduction Goals of the Act;
(3) there is evidence of any action, direct or indirect, taken by the
state to undermine the achievement of the Retail Compliance Check
Performance Targets and Youth Smoking Reduction Goals or other
terms and objectives of the Act; and
(4) any other relevant evidence.
The burden shall be on the state to prove, by a preponderance of the
evidence, that the state should be granted a release and disbursement
of the Withhold Amount or any portion thereof. Prior to decision, the
agency shall hold a hearing on the petition, with notice and opportu-
nity to be heard given to the attorney general of that state and to all
domestic tobacco product manufacturers.
Upon a finding by the agency that the state meets the grounds, as set
forth above, and the burden of proof for a release and disbursement
of a Withhold Amount, then it shall order a release and disbursement
of up to 75% of the Withhold Amount appealed, and it shall so re-
lease and disburse to the state that amount, with interest at the aver-
age United States 52-Week Treasury Bill rate for the period between
notice and release of such Withhold Amount. The agency may con-
sider all relevant evidence in determining that percentage of the With-
hold Amount to order released and disbursed,
Any manufacturer or state attorney general aggrieved by a Withhold
Amount decision of the agency may seek judicial review thereof within
30 days in the United States Court of Appeals for the District of Co-
lumbia Circuit. Unless otherwise specified in this Act, judicial review
under this Section shall be governed by Sections 701-706 of Title 5 of
the United States Code.
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No stay or other injunctive relief enjoining imposition of the withhold
pending appeal or otherwise may be granted by the FDA or any court.
No appeal may be taken from an agency decision denying a petition
to release and disburse a Withhold Amount unless filed within 30 days
following notice of such decision. No stay or other injunctive relief,
enjoining imposition of the withhold pending appeal or otherwise,
may be granted, by any court or administrative agency. Appeals filed
hereunder shall be made to the District of Columbia Circuit Court of
Appeals and, on appeal, shall be governed by the procedural and evi-
dentiary provisions of the Administrative Procedures Act, unless other-
wise specified in this Act. The judgment of the District of Columbia
Court of Appeals on appeal shall be final.
